Study of plasma concentration of Imatinib in Chinese patients with gastrointestinal stromal tumor

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RNC-14004667

Enrollment

Unknown

Registered

2014-09-21

Start date

2014-06-01

Completion date

Unknown

Last updated

2018-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal stromal tumor

Interventions

Group A:Imatinib

Eligibility

Sex/Gender

Male

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. diagnosed as GIST by histopathology; 2. going to receive or has received Imatinib; 3. classified as moderate/high risk of recurrence; 4. ECOG score 0-2; normally functioning organ; 5. Aged 18 to 75 years; Signed informed consent.

Exclusion criteria

Exclusion criteria: 1.active infection; 2.pregnancy or lactation; 3.severe organ dysfunction or over 3 times more than upper limit of ALT/AST; 4.participate in the other clinical trial simultaneously or 4 weeks before this tiral; 5.quit for a reason.

Design outcomes

Primary

Measure	Time frame
plasma concentration;progression-free survival;overall surviva;	—

Countries

China

Contacts

Public ContactZekuan Xu

The First Affiliated Hospital of Nanjing Medical University

xuzekuan@njmu.edu.cn+86 025 83781992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026